Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cormedix Inc (NQ: CRMD )

5.180 +0.180 (+3.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 290,950
Open 4.990
Bid (Size) 5.010 (1)
Ask (Size) 5.240 (1)
Prev. Close 5.000
Today's Range 4.973 - 5.240
52wk Range 2.645 - 8.025
Shares Outstanding 38,086,437
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
As CorMedix's DefenCath Moves Forward On Regulatory Path, Analyst Boosts Price Target
Tuesday, CorMedix Inc (NASDAQ: CRMD) resubmitted New Drug Application for DefenCath to the FDA, and the submission has been acknowledged as  
Via Benzinga
What 5 Analyst Ratings Have To Say About Cormedix
 
Via Benzinga

Performance

YTD
+23.92%
+23.92%
1 Month
-1.33%
-1.33%
3 Month
+37.77%
+37.77%
6 Month
+37.04%
+37.04%
1 Year
+62.38%
+62.38%

More News

Read More
CorMedix (CRMD) Q1 2023 Earnings Call Transcript
Via The Motley Fool
Recap: Cormedix Q1 Earnings
Via Benzinga
Preview: Cormedix's Earnings
Via Benzinga
Citius Pharmaceuticals Approaches End Of Trial For Catheter-Related Bloodstream Infections – How Are Analysts Scoring Its Stock?
Via Benzinga
7 Small-Cap Biotech Stocks with Massive Potential
Via InvestorPlace
Expert Ratings for Cormedix
Via Benzinga
Cormedix's Return On Capital Employed Overview
Via Benzinga
A Preview Of Cormedix's Earnings
Via Benzinga
Cormedix's Return On Capital Employed Insights
Via Benzinga
7 Biotech Stocks With Huge Return Potential for Long-Term Investors
Via InvestorPlace
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
Via Benzinga
CorMedix Inc Common Stock (CRMD) Q3 2022 Earnings Call Transcript
Via The Motley Fool
CorMedix Inc. (NASDAQ:CRMD) Shareholder Alert: Investigation over Potential Wrongdoing
Via SBWire
CorMedix Inc. (NASDAQ:CRMD) Shareholder Notice: Update in Lawsuit Announced
Via SBWire
Recap: Cormedix Q2 Earnings
Via Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,100 Today
Via Benzinga
Dow Drops Over 100 Points; Verona Pharma Shares Jump
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Via Benzinga
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Nasdaq Tumbles 1.5%; BBQ Holdings Shares Spike Higher
Via Benzinga
Why U.S. Stocks Are Trading Mixed; Labor Costs Increase Higher-Than-Expected In Q2
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.